2-Pyridinylmethylsulfinylbenzimidazoles
"2-Pyridinylmethylsulfinylbenzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that contain benzimidazole joined to a 2-methylpyridine via a sulfoxide linkage. Several of the compounds in this class are ANTI-ULCER AGENTS that act by inhibiting the POTASSIUM HYDROGEN ATPASE found in the PROTON PUMP of GASTRIC PARIETAL CELLS.
Descriptor ID |
D053799
|
MeSH Number(s) |
D02.886.640.074 D03.383.725.024 D03.633.100.103.034
|
Concept/Terms |
2-Pyridinylmethylsulfinylbenzimidazoles- 2-Pyridinylmethylsulfinylbenzimidazoles
- 2 Pyridinylmethylsulfinylbenzimidazoles
- Benzimidazole Methylpyridine Sulfoxides
- Methylpyridine Sulfoxides, Benzimidazole
- Sulfoxides, Benzimidazole Methylpyridine
Timoprazole Derivatives- Timoprazole Derivatives
- Timoprazoles
- 2-Methylpyridine 2-Benzimidazole Sulfoxides
- 2 Methylpyridine 2 Benzimidazole Sulfoxides
- 2-Benzimidazole Sulfoxides, 2-Methylpyridine
- Sulfoxides, 2-Methylpyridine 2-Benzimidazole
- 2-Pyridinylmethylsulfinyl-2-Benzimidazoles
- 2 Pyridinylmethylsulfinyl 2 Benzimidazoles
|
Below are MeSH descriptors whose meaning is more general than "2-Pyridinylmethylsulfinylbenzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "2-Pyridinylmethylsulfinylbenzimidazoles".
This graph shows the total number of publications written about "2-Pyridinylmethylsulfinylbenzimidazoles" by people in this website by year, and whether "2-Pyridinylmethylsulfinylbenzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2007 | 1 | 0 | 1 |
2008 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "2-Pyridinylmethylsulfinylbenzimidazoles" by people in Profiles.
-
Somberg L, Morris J, Fantus R, Graepel J, Field BG, Lynn R, Karlstadt R. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma. 2008 May; 64(5):1202-10.
-
Watari J, Das KK, Amenta PS, Tanabe H, Tanaka A, Geng X, Lin JJ, Kohgo Y, Das KM. Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol. 2008 Apr; 6(4):409-17.
-
DeVault KR, Morgenstern DM, Lynn RB, Metz DC. Effect of pantoprazole in older patients with erosive esophagitis. Dis Esophagus. 2007; 20(5):411-5.
-
Pratha V, Hogan DL, Lynn RB, Field B, Metz DC. Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. Dig Dis Sci. 2006 Sep; 51(9):1595-601.
-
Pratha VS, Hogan DL, Lane JR, Williams PJ, Burton MS, Lynn RB, Karlstadt RG. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults. Dig Dis Sci. 2006 Jan; 51(1):123-31.
-
McDonald JM, Longnecker DS, Bell RH. Effect of hypergastrinemia on pancreatic carcinogenesis. Am J Surg. 2002 Apr; 183(4):441-4.
-
Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci. 2000 May; 45(5):845-53.
-
Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther. 1999 Feb; 13(2):179-86.
-
Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1999 Jan; 13(1):49-57.
-
Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1998 Aug; 12(8):789-95.